The newspaper el Economista has devoted a column to the first Master's Degree in Experimental Sciences that has been set up by the Barcelona Institute of Science and Technology (BIST) and the Pompeu Fabra University. The programme includes a Winter School on microscopy, nanoscopy and image sciences, which will be given by specialists from ICN2, IRB Barcelona, CRG, ICFO and IFAE.
Today Nature Index has published statistics indicating the scientific attractiveness of Barcelona and the scientific rivalry with Madrid. The subheading notes "Barcelona lures scientists, while Madrid is bound by bureaucracy."
Among the different rankings, the report lists the ten best scientific institutions in Barcelona and classifies the Institute of Biomedical Research in eight place. The Institute is one of the four centres participating in Barcelona Institute of Science and Technology (BIST) that appears in the "top ten."
LaCerca.com has echoed on the 25 centres—among them IRB Barcelona—and the 16 research units accredited with the distinctions of excellence " Severo Ochoa" and " María de Maeztu", respectively, which have set up the Severo Ochoa and María de Maeztu Alliance. Among other objectives, this alliance seeks to promote the exchange of knowledge, technology and good practices and have a voice in Spanish and European scientific politics.
Link to LaCerca.com
Several media, including Canal Diabetes, has dedicated an article to the first joint meeting of the French, Portuguese and Spanish Biochemistry and Molecular Biology Societies (FEBS3+), which will take place in the Palau de Congressos of the Fira de Barcelona from 23 to 26 October. Gathering top scientists, the meeting will be presided by Antonio Zorzano, group leader at IRB Barcelona and coordinator of the Molecular Medicine Programme, as well as professor at the University of Barcelona and CIBER for Diabetes and Associated Metabolic Diseases.
Link to Canal Diabetes
Link to ...
The radio programme Te doy mi palabra broadcasted by Onda Cero has referred to a study by ICREA researcher Salvador Aznar Benitah. Published in Nature in December 2016, the research revealed that consuming certain fats stimulates metastasis. Aznar Benitah’s team reached this conclusion after examining the effect of dietary fatty acid intake in mice.
Link to Te doy mi palabra (Onda Cero)
The website La Nueva España has echoed the participation of Joan Guinovart, director and researcher at IRB Barcelona, in Science Week in Valdés, Asturias. Guinovart will kick off the event with a talk about diabetes. Science Week will be held from 10 to 15 November.
Link to La Nueva España
The prize is shared between American scientists Jeffrey C Hall, Michael Rosbash and Michael W Young for work on the internal clock of living organisms, using the fruit flies for their research.
Their discoveries explain how plants, animals and humans adapt their biological rhythm to synchronise with the rotation of the Earth.
The biological clock helps to regulate sleep patterns, feeding behaviour, hormone release and blood pressure.
Salvador Aznar Benitah, scientist at IRB Barcelona studying the day-night cycle in adult stem...
The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.
The magazine Cuerpo Mente has highlighted the study published in Nature in December 2016 by the group headed by ICREA researcher Salvador Aznar Benitah. He and his team analysed the impact of fatty acid intake on metastasis in mice. The results revealed that there is a relationship between diet and the metastatic potential of tumours.
Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Link to Innovaspain.com